Comparative Pharmacology
Head-to-head clinical analysis: MS CONTIN versus SUFENTA PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MS CONTIN versus SUFENTA PRESERVATIVE FREE.
MS CONTIN vs SUFENTA PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; binds to mu-opioid receptors in the CNS, modulating pain perception and emotional response to pain.
Sufentanil is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors in the central nervous system, leading to activation of descending pain pathways and inhibition of nociceptive transmission.
Oral: 15-30 mg every 8-12 hours; adjust based on pain severity and prior opioid use. Extended-release tablets must be swallowed whole; do not crush or chew. For opioid-naïve patients, start at 15 mg every 12 hours.
1-2 mcg/kg IV initially, then 0.15-0.3 mcg/kg/min IV infusion; doses up to 8 mcg/kg for anesthesia induction.
None Documented
None Documented
Terminal elimination half-life: 11-13 hours (range 8-24 hours). In elderly or hepatic impairment, half-life may be prolonged; acute dosing half-life ~2-4 hours.
Terminal elimination half-life is approximately 2.5-3.5 hours in adults, 3-4 hours in neonates; clinical context: context-sensitive half-life increases with infusion duration (e.g., ~30 minutes after 2-hour infusion, ~45 min after 8-hour infusion).
Renal: ~90% (mostly as morphine-3-glucuronide and morphine-6-glucuronide, with ~10% as unchanged morphine); Fecal: <10%
Renal (metabolites, <1% unchanged) and biliary; sufentanil is extensively metabolized in liver via N-dealkylation and O-demethylation, with metabolites primarily excreted in urine (approximately 80%) and feces (approximately 20%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic